← Back
Data updated: Jun 28, 2026
FAMYGEN LIFE SCI
Pharma Pharmaceuticals
FAMYGEN LIFE SCI is a pharmaceutical company with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FAMYGEN LIFE SCI's Key Drugs
FAMYGEN LIFE SCI's core commercial portfolio centers on RYZUMVI — its most strategically important drugs approved in the last 15 years.
FAMYGEN LIFE SCI's Recent FDA Approvals
New NDA/BLA approvals for FAMYGEN LIFE SCI over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
FAMYGEN LIFE SCI's Therapeutic Areas
Disease areas where FAMYGEN LIFE SCI has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
FAMYGEN LIFE SCI Pipeline Snapshot
Active clinical trials for FAMYGEN LIFE SCI across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RYZUMVI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-09-25
- Latest
- 2023-11-28
- Applications
- 1